In clinical practice, the only currently approved tissue biomarker consists of the evaluation of the PD-L1 tumor proportion score (TPS), which is assessed using immunohistochemistry (patients with a ≥50% PD-L1 expression are generally candidates for ICI monotherapy). Here, CD274 is linked to neoplasm.